Table 3.
TACE with uveal melanoma
| Authors | Patients, n | Technique | Mean number of sessions | Survival |
|---|---|---|---|---|
| Schuster et al. [33] | 25 | fotemustine-based or cisplatin-based TACE | median overall survival was 6 months, 15% of patients alive at 1 year | |
| Huppert et al. [34] | 14 | 100 mg/m2 of cisplatin + embolization by polyvinyl alcohol particles | 2.4 treatments | median survival after first TACE was 11.5 months |
| Fiorentini et al. [35] | 10 | TACE + DC beads + irinotecan | 6.5 months (range 4–9 months) | 5 months |
| Vogl et al. [36] | 12 | mitomycin C, lipiodol, resorbable microspheres | 3-month intervals | mean survival following primary tumor treatment was 32.9 months |
| Patel et al. [37] | 30 | 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) dissolved in ethiodized oil; gelatine sponge | 24 | median overall survival of the entire intention-to-treatment group of patients was 5.2 months |